Shanks N, Macklin J, Coles S
University of Sheffield Medical School, England.
Clin Ther. 1989 Nov-Dec;11(6):812-9.
Seven hundred fifty patients with acute upper or lower respiratory tract infections were randomly assigned to receive 2 gm of erythromycin ethylsuccinate daily or 1.125 gm of clavulanate-potentiated amoxicillin daily in a single-blind, multicenter study. The efficacy of each formulation was similar, with close to 90% of patients in each treatment group being reported as either cured or improved. Gastrointestinal symptoms were the most commonly reported side effects, their overall incidence being similar in both treatment groups. However, diarrhea occurred more than twice as often in the amoxicillin group than the erythromycin group. In each group, the number of patients failing to complete treatment was similar; the main reasons cited for discontinuation were gastrointestinal symptoms. The results indicate that both erythromycin ethylsuccinate and clavulanate-potentiated amoxicillin are well tolerated and are equally effective for routine empirical treatment of acute respiratory tract infections.
在一项单盲、多中心研究中，750例急性上呼吸道或下呼吸道感染患者被随机分配，分别每日接受2克琥乙红霉素或1.125克克拉维酸增强型阿莫西林治疗。每种制剂的疗效相似，每个治疗组中近90%的患者报告治愈或病情改善。胃肠道症状是最常报告的副作用，两个治疗组的总体发生率相似。然而，阿莫西林组腹泻的发生率是红霉素组的两倍多。每组中未完成治疗的患者数量相似；停药的主要原因是胃肠道症状。结果表明，琥乙红霉素和克拉维酸增强型阿莫西林耐受性良好，在急性呼吸道感染的常规经验性治疗中同样有效。
